Argus analyst David Toung raised the firm’s price target on Labcorp (LH) to $290 from $260 and keeps a Buy rating on the shares after its Q4 earnings beat. The firm believes that higher diagnostics volumes and positive pricing will drive growth for the company in 2025, and with market sentiment going negative for high-multiple equities, Argus sees upside for Labcorp shares which trade at just 14.4-times its expected forward earnings, the analyst tells investors in a research note. Both Diagnostics and Biopharma Lab Services Labcorp businesses are seeing solid volume growth and higher margins, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz
- Okta upgraded, Quest Diagnostics downgraded: Wall Street’s top analyst calls
- Labcorp upgraded to Buy from Neutral at Citi
- Labcorp announces clinical availability of liquid biopsy test
- Labcorp price target raised to $260 from $240 at Piper Sandler